Boulder startup Sinopsys Surgical raises $8.3 million

BOULDER – Medical-device startup Sinopsys Surgical Inc. has raised $8.3 million in equity funding, according to a regulatory filing made Friday with the Securities and Exchange Commission.

Houston-based MercuryFund, an investment firm that lists Boulder-based Sinopsys among its portfolio companies, states on its website that the stealth-mode startup is developing a minimally invasive surgical procedure. According to a report on medical-device website MassDevice.com, that procedure reroutes the tear duct to drain into the sinus to aid in the treatment of chronic sinusitis.

Sinopsys Surgical startup president Harry Ross told BizWest Friday that he could not say much about the company other than issuing an emailed statement.

SPONSORED CONTENT

People Powered: Preparing Longmont Businesses for Economic Success

Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.

“Sinopsys Surgical is grateful for the enthusiasm and confidence of its investors,” Ross said in the note. “The company will be initiating U.S. clinical trials in Chronic Rhino-sinusitis and Epiphora augmenting its existing FDA clearances.”

Boulder-based High-Country Ventures, Superior-based Aweida Venture Partners and MercuryFund all have board seats with Sinopsys, according to the SEC filing.

Founded in 2011, Sinopsys in 2012 raised $1.2 million in equity before completing a $600,000 debt raise in October of last year.